NEEDHAM, Mass. -
Sept. 15, 2020 -
PRLog -- BostonSight
®, a nonprofit eye healthcare organization and research center dedicated to saving sight and improving quality of life for patients, announced today they have added three PROSE™ Provider sites and four PROSE Clinical Fellows to the BostonSight PROSE Network. With this addition, the BostonSight PROSE Provider Network now includes 18 sites in four countries.
BostonSight PROSE is a custom medical treatment model that saves sight in individuals with ocular surface disease. During treatment, doctors customize prosthetic devices from gas-permeable polymers for each patient's condition and unique eye shape.
For many people, PROSE treatment is their only option to restore visual function and end suffering from critical and devastating eye issues resulting from complications with dry eye, keratoconus, ocular GVHD, Sjögren's Syndrome, Stevens Johnson Syndrome, corneal damage or injury, and other corneal diseases.
PROSE treatment teams include cornea specialist ophthalmologists and optometrists who have completed an intensive BostonSight PROSE Clinical Fellowship.
"Our mission at BostonSight is to expand our network of PROSE providers, elevate the standard of patient care, and improve quality of life for those who are suffering from corneal irregularities or ocular surface disease," said Sara Yost, BostonSight President and CEO. "We are excited to welcome our newest PROSE Network Clinics and Fellows to provide broader access to this life-changing treatment. The new Fellows are highly regarded and experienced in the treatment of ocular surface disease and will continue to provide the expert level of care for which PROSE treatment has been recognized."
Among the additions, the BostonSight PROSE Network now includes:
- Dr. Lee Guo. Dr. Guo joins the previously established PROSE site at the Johns Hopkins Wilmer Eye Institute in Baltimore, MD. He is currently an assistant professor within the department of Cornea, Cataract, and External Diseases. Dr. Guo is also among clinical faculty in the multidisciplinary Johns Hopkins Sjögren's Center and the Wilmer Ocular Surface Diseases and Dry Eye Team. He received his Doctor of Optometry degree from Nova Southeastern University and completed ocular disease residency at C.W. Bill Young VAMC in Bay Pines, FL. Dr. Guo currently assists as research investigator to various active dry eye studies and provides patient care at Wilmer Eye Institute locations in the Johns Hopkins Hospital and Bayview Medical Center in Baltimore. https://www.hopkinsmedicine.org/profiles/results/directory/profile/10004625/lee-guo
- Dr. Robert Davis and Davis EyeCare in Chicago, IL. Dr. Davis is the medical director at the Contact Lens Clinic at Davis EyeCare. He is also co-founder of EyeVis, Eye and Vision Research Institute, developing novel contact lens designs as well as forging the knowledge of anterior segment pathophysiology. Dr. Davis has been recognized as a Diplomate in the Corneal, Contact Lens and Refractive Technology section of the American Academy of Optometry as well as an inductee in National Academy Practice in Optometry. He is an adjunct faculty member at Southern California College of Optometry - Marshall B. Ketchum University, Illinois College of Optometry, Pennsylvania College of Optometry at Salus University, and Pacific University. He has held leadership roles in the American Optometric Association, American Academy of Optometry, National Academy of Practice, and other professional organizations. https://daviseyecare.com/
- Dr. John D. Gelles and the Cornea and Laser Eye Institute (CLEI) Center for Keratoconus in Teaneck, NJ. Dr. Gelles is a graduate of the Pennsylvania College of Optometry and is a Clinical Assistant Professor at Rutgers New Jersey Medical School Department of Ophthalmology and Visual Science. He an adjunct clinical professor at State University of New York College of Optometry, Illinois College of Optometry and New England College of Optometry. Dr. Gelles is clinical investigator for various keratoconus and specialty contact lens clinical trials and is active nationally with a number of professional organizations related to keratoconus and contact lens. Dr. Gelles is committed to helping individuals affected by complex corneal and ocular surface diseases through the utilization of advanced contact lenses, treatments, therapies, and the latest technologies to improve quality of life. With a team of specialized ophthalmologists, Dr. Peter S. Hersh, Dr. Steven A. Greenstein, and Dr. David S. Chu, CLEI provides comprehensive corneal and ocular surface disease care. https://www.vision-institute.com/
A full list of PROSE Network Sites can be found on the BostonSight website at
www.bostonsight.org.
About BostonSight®BostonSight
has saved the sight of thousands of individuals suffering from ocular surface disease, corneal disease, injury, or damage with
BostonSight
PROSE
™ treatment. Founded in 1992, the Needham, MA Center of Excellence includes a clinic, research center, state-of-the-
art FDA-certified and ISO-compliant
manufacturing lab, and patient and family support center. BostonSight
SCLERAL was
launched in 2017 to expand access to global scleral lens technology.
Eye care practitioners achieve a fast, effective
scleral lens fit that provides optimal vision and comfort for patients while attaining long-term eye
health. SCLERAL
IG is the newest innovation in BostonSight's portfolio, using image topography to map the eye for a truly custom scleral lens fit. BostonSight envisions a world where no one suffers loss of sight from corneal irregularities or ocular surface disease. Learn more at
www.bostonsight.org.